je.st
news
Tag: vytorin
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
2015-03-16 20:30:00| Merck.com - Product News
Dateline City: SAN DIEGO SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
2015-02-25 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the companys cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San Diego. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck's Vytorin first cholesterol drug to cut risk further
2014-11-18 09:37:30| Biotech - Topix.net
Merck & Co.' s Vytorin reduced the risks of second heart attacks and strokes in patients already on aggressive therapy, making it the first medicine to improve on the current standard of care for lowering cholesterol.
VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
2014-11-17 17:45:00| Merck.com - Product News
Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
events
study
reduced
Study lifts cloud over heart drugs Zetia, Vytorin
2014-11-17 16:58:04| Biotech - Topix.net
This 2004 file photo provided by Schering-Plough Corp. shows the cholesterol-lowering drug Vytorin. A major study gives a long-awaited answer on whether the blockbuster drugs Vytorin and Zetia lower the risk of heart problems.